Abstract
Phase 1/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have